Ann: Race releases complete cardio-protection data & video, page-204

really good argument and in this day and age, "porque no los dos?", why can't we have both ?

Triangle discounted the cardio protect value by 50%, so why can't we have one BP paying 50% upfront, USD5-8B, and the remaining 50%, $5-8B, paid out in royalties on a sliding scale, ie. majority paid out in bisantrene's patent life and less when generics come into play?

same goes for FTO and $1B AML

certainly a lot more digestible...

AbbVie paid USD22B for only 50% of Pharmacyclics and the other 50% was owned by J&J, instos and SHs who enjoyed royalties/divies of some sort